A Study of LP-168 in Participants With Relapse or Refractory B-Cell Lymphoma

This study tests a new oral drug called LP-168 in patients with various types of B-cell blood cancers (including diffuse large B-cell lymphoma, follicular lymphoma, chronic lymphocytic leukemia, mantle cell lymphoma, and others) that have relapsed or are no longer responding to previous treatments. **You may be eligible if...** - You are 18 or older with a confirmed B-cell lymphoma or leukemia diagnosis - For DLBCL or follicular lymphoma: your cancer has relapsed or stopped responding after at least 2 prior treatments - For other B-cell cancers (CLL, SLL, MCL, MZL, WM): after at least 1 prior treatment - You have adequate blood, liver, and kidney function - You are able to take oral medication and willing to attend required exams **You may NOT be eligible if...** - You have Burkitt lymphoma, lymphoblastic leukemia, or post-transplant lymphoma - You had another cancer in the past 3 years (except certain treated skin or cervical cancers) - You have active HIV, hepatitis B, hepatitis C, or active infections - You are pregnant or breastfeeding - You have significant heart problems or prolonged QT interval on ECG - You cannot swallow the study drug or have severe gastrointestinal problems Talk to your doctor to see if this trial is right for you.